JPMorgan raised the firm’s price target on Cytokinetics (CYTK) to $70 from $55 and keeps an Overweight rating on the shares. The firm upped the price target after revisiting its epidemiology and diagnosis rate assumptions for obstructive and nonobstructive hypertrophic cardiomyopathy. Diagnosis trends indicate nonobstructive hypertrophic cardiomyopathy is growing at a faster rate than obstructive and could account for up to half of the total HCM market over time, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
- Cytokinetics price target raised to $62 from $56 at BofA
- Cytokinetics’ Aficamten Faces Competitive and Regulatory Challenges: Hold Rating Maintained
- Verisign, HEICO, Transdigm, Albertsons, Cytokinetics: Insider Moves Unveiled!